TY  - CONF

T1  - Dupilumab Efficacy and Safety up to 2 Years in Children Aged 6 Months to 5 Years With Moderate-to-Severe Atopic Dermatitis

JO  - CRITICAL PUBLIC HEALTH

PY  - 2024/01/01

AU  - Su JC

AU  - Paller AS

AU  - Simpson EL

AU  - Siegfried EC

AU  - Cork MJ

AU  - Arkwright PD

AU  - Pinter A

AU  - Dubost-Brama A

AU  - Chen Z

AU  - Bansal A

AU  - Prescilla R et al

ED  - 

VL  - 34

IS  - 1

SP  - 14

EP  - 15

Y2  - 2025/04/30

ER  -